Plain-English translation of NCT05906576 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a real-world registry study following children in China who are receiving , an injectable biologic medication used to treat Crohn's disease. The study will track how well the medication works and how safe it is over the course of about two years. Researchers want to understand how this treatment performs in everyday clinical care, not just in a controlled research setting.
Crohn's disease can cause serious inflammation in children's digestive systems, and this medication has been approved to help treat it. This study exists to gather real-world evidence about how well the treatment works for Chinese children and to identify any safety concerns that might not have been caught in earlier trials.
You likely qualify if…
You likely don't qualify if…
You would receive injections as prescribed by your doctor and be monitored closely for about two years (102 weeks). During this time, you would have regular clinic visits where doctors would check how you're responding to the treatment, watch for any side effects, and collect information about your symptoms and disease activity. The study is tracking your real-world experience with the medication rather than asking you to change how you normally receive care.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Enrollment target
~30 participants
Started
September 2023
Primary completion
November 2026
Age range
6 Years – 17 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wu Jie
Beijing Children's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.